Korro Bio (KRRO) Insider Francois Sells $1.7M of Stock

Formela Jean Francois sold 119,005 shares of Korro Bio, Inc. (KRRO) on June 23, 2026. The transaction was valued at roughly $1.69 million and was disclosed in a recent filing with the SEC. This sale is part of a series of transactions by this individual during the same week.

A Series of Planned Transactions

This sale of 119,005 shares follows a smaller sale of 3,962 shares just one day earlier on June 22, 2026. The selling continued on June 24, 2026, when Formela Jean Francois offloaded another 48,438 shares at a price of $14.60. All of these trades were executed under a Rule 10b5-1 trading plan, which is a tool that allows insiders to schedule stock sales in advance to avoid any appearance of trading on private information.

Korro Bio Stock Trends

On Thursday, Korro Bio shares were trading at $13.77. The stock has seen a wide range over the past year, hitting a low of $5.20 and reaching as high as $55.89. The current price sits above the 50-day moving average of $12.40 and the 200-day moving average of $11.58, suggesting some recent upward momentum compared to the longer-term trend. The company currently has a market value of roughly $146.96 million.

Recent Earnings and Financials

Korro Bio reported revenue of $2.38 million in its most recent disclosures. The company is not currently profitable, reporting a net loss with an earnings per share (EPS) of -$9.88. Because it is not earning a profit, it does not have a meaningful P/E ratio. The company's next earnings report is expected on November 12, 2026. Despite the lack of current profits, the firm maintains a current ratio of 9.55, which means it has a large amount of cash and short-term assets relative to its immediate debts.

Other Insider Activity at Korro Bio

Formela Jean Francois isn't the only person at the company who has been selling lately. On June 16, 2026, several other executives sold shares on the same day. Chief Operating Officer Todd Chappell sold 3,168 shares at $10.83 each. Chief Scientific Officer Loic Vincent also sold 3,418 shares at that same price, while Oliver Dolan, the Senior Vice President of Finance, sold 3,383 shares. These executive sales were smaller in scale than the transactions made by Formela Jean Francois.

Analysts Set New Price Targets

Analysts have generally kept a positive outlook on the stock. On October 6, 2026, HC Wainwright & Co. reiterated a Buy rating with a $15.00 price target. This followed an earlier report from the same firm on August 20, 2026, which also carried a Buy rating and the same price target. Among the 10 analysts covering the company, the average price target is $20.20, with some estimates reaching as high as $30.00.

About Korro Bio

Korro Bio is a biotechnology company that works on genetic medicines. It uses a special platform to edit RNA, which is a way to treat diseases without changing a person's underlying DNA. The company is currently focused on treatments for rare diseases and conditions like Parkinson's and chronic pain. Their most advanced work is a program called KRRO-121, aimed at treating a rare metabolic disorder.

What's Ahead for Korro Bio, Inc.

Investors often watch insider sales to see how the people closest to a company are managing their own holdings. While these sales were planned in advance, they represent a significant reduction in Formela Jean Francois's stake during the month of June. The next major update for the company will likely be its November 12 earnings report, where investors will look for progress on its clinical programs and its partnership with Novo Nordisk.